Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. It has a partnership with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
IPO Year: 2014
Exchange: NASDAQ
Website: biocept.com
SC 13G - BIOCEPT INC (0001044378) (Subject)
3 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
3 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
4 - BIOCEPT INC (0001044378) (Issuer)
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (NASDAQ:PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord. CNSide is Biocept's proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration p
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Biocept
Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers.
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update. "Biocept's primary focus is establishing our proprietary cerebrospinal fluid assay CNSide™ as standard of care. We continue to diligently work towards submission to the National Comprehensive Cancer Network® (NCCN®) for consideration to include CNSide in their standard-of-care guidelines. We believe securing this status will broaden physician adoption and support reimbursement that reflects our test's value in clinical decision-making," said Antonino Morales, Biocept President and C
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company") announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board of Directors and staff of Biocept extend their deepest condolences to the Wilson family and express their gratitude for her many contributions to Biocept. Ms. Wilson was appointed to Biocept's Board in 2009 and served at various times as Lead Independent Director and as Chair. Most recently, in addition to her role as Board Chair, she was a member of the Audit, Compensation, and Science and Technology Committees. "It is with deep sadness that we announce Faye's passing," said Antonino Morales, Biocept President and CEO. "I had the gr
Samuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer,
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept's discussion will be hosted by Maxim Group Senior Research Analyst Michael Okunewitch. Registration information to become an M-Vest member for access to the live and archived presentation webcast is posted to Events & Presentations section of the Biocept website. About M-Vest M-Vest is a division of Maxim Group LLC that serves to allows investors access to investment opportu
Real-world retrospective study showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago showing the ability of CNSide™ to detect rates of leptomeningeal metastases (LM) compared with standard CSF cytology from lumbar puncture. The poster, titled "Evaluating the diagnostic performance of leptomeningeal diagnosis with CNSide compared to standard cytology," was p
Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten public offering of 1,176,470 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,352,940 shares of its common stock at a combined offering price of $4.25 per share (or pre-funded warrant in lieu thereof) and an accompanying warrant to purchase two shares of common stock. The warrants will have a per share exercise price of $4.25, are exercisable immediately, will expire five years from the date of issuance and contain an alternative cashless exercise provisi
Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international callers.
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. "I'm exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide™'s clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we've now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area," said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. "In our q
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. "I could not be prouder of my Biocept colleagues as together we have worked tirelessly to streamline operations, prioritize decisions to advance our corporate mission and carefully manage expenditures. We are more convinced than ever that our proprietary CNSide™ assay will improve the lives of patients with cancers that have metastasized to the central nervous system. To support this conviction, we have completed our evaluation of strategic alternatives and determined that the best course
CNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting Participates in UCSF investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system CNSide orders increased 8% over 2Q 2022 and 176% versus 3Q 2021 Conference Call to be held November 28, 2022 at 4:00 p.m. Eastern time Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a business update. "Our third quarter financial results reflect solid increases in CNSide orders,
Included first revenue from biopharma collaborator using CNSide™ in their therapeutics clinical trial First site opened for patient enrollment in the FORESEE trial to generate evidence of CNSide's clinical utility Expanded the commercial availability of CNSide to metastatic melanoma CNSide™ orders increased 14% over 1Q 2022 and 212% versus 2Q 2021 Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business update. "Today we are reporting strong progress in positioning Biocept as a leader in neurological tumor diagnostics," said Samuel D. Ric
Biocept, Inc. (NASDAQ:BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. The conference call can be accessed at the time of the live call by dialing (855) 656-0927 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4109 for other international cal
Net revenues of $19.9 million up 12% over Q1 2021 CNSide™ assay volume up 219% over Q1 2021 and up 70% over Q4 2021 Expanded CNSide customer base with additional oncologists from six leading cancer centers Previews re-focused and rationalized strategy following comprehensive business review Business update conference call to be held June 7, 2022 at 4:00 p.m. ET Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update. "Net revenues for the first quarter increased 12% to $19.9 million, driven by RT-PCR COVID-19 testing services," said Sam
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept's financial statements as of and for the three months ended March 31, 2022, which ongoing review is a result of a change in circumstances at the U.S. Health Resources Services Administration (HRSA) and the resulting impact on its funding for reimbursement for COVID-19 testing services, including those performed by Biocept. Biocept expects to file its Form 10-Q on or before May 23, 2022. The company intends to issue
Fourth quarter net revenues of $14.0 million driven by RT-PCR COVID-19 testing volume Full year net revenues of $61.2 million increased 123% over the prior year Positive operating cash flow for 2021 of $3.7 million Cash and cash equivalents at 2021 year-end of $28.9 million CNSide™ sequential-quarter volume growth continued; academic customer base expanded Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business update. "During the fourth quarter we expanded our CNSide customer base to include several additional prestigious academic
Biocept, Inc. (NASDAQ:BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022. Management will not hold an investment community conference call with the reporting of 2021 fourth quarter and full year financial results. Biocept plans to announce financial results for the three months ended March 30, 2022 in mid-May 2022. Management plans to hold an investment community conference call in conjunction with reporting first quarter 2022 financial results in which it plans to unveil the company's rationalized business strate
8-K - BIOCEPT INC (0001044378) (Filer)
8-K - BIOCEPT INC (0001044378) (Filer)
8-K - BIOCEPT INC (0001044378) (Filer)
10-Q - BIOCEPT INC (0001044378) (Filer)
8-K - BIOCEPT INC (0001044378) (Filer)
424B4 - BIOCEPT INC (0001044378) (Filer)
EFFECT - BIOCEPT INC (0001044378) (Filer)
S-1/A - BIOCEPT INC (0001044378) (Filer)
S-1/A - BIOCEPT INC (0001044378) (Filer)
S-1/A - BIOCEPT INC (0001044378) (Filer)
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte
Samuel D. Riccitelli resigns as interim President and CEO, and Director Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, has named Antonino Morales as President and Chief Executive Officer, effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer,
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept's Audit Committee. "Quyen's extensive financial experience leading accounting and finance departments, and overseeing technical accounting, budgeting and forecasting, financial modeling, cash management and SEC reporting, make her a valuable addition to our Board and its Audit Committee," said Samuel D. Riccitelli
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the "Notice") on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising Biocept that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the "Rule") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the "Form 10-Q") in a timely manner. The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). Biocept previo
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP ("RSM") as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th straight year by Accounting Today. RSM replaces Mayer Hoffman McCann P.C. ("MHM"), which notified the company on April 7, 2022 of its decision to decline to stand for re-appointment as the company's independent registered public accounting firm. The decision by MHM was not the result of any disagreement with the company. MHM's audit reports on the company
Industry veteran to oversee operations for the company and its CNSide™ cerebrospinal fluid assay to aid in the management of patients with metastatic brain cancers Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Philippe Marchand, Ph.D., to the position of Chief Operating Officer, effective today. Dr. Marchand will be responsible for advancing the company's strategic and operational objectives, including all laboratory operations of its CNSide cerebrospinal fluid assay, which helps physicians better detect and manage treatment of patients with metastatic cancers involving the central nervous system. "Biocept is excited t
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointments of Samuel D. Riccitelli as Interim President and Chief Executive Officer, succeeding Michael W. Nall, and Antonino Morales as Interim Chief Financial Officer, succeeding Timothy C. Kennedy. Biocept also named M. Faye Wilson as Lead Independent Director of the company's Board of Directors. Mr. Riccitelli remains Chair of the Board. "I am grateful and excited to see Sam and Antonino stepping into their interim roles at a time when Biocept is fulfilling such an important mission for our current COVID-19 testing clients and I am even more excited about what their le
New York, March 02, 2021 (GLOBE NEWSWIRE) -- - Energy Fuels Inc (NYSEAMERICAN:UUUU) (TSE:EFR) signs deal with Neo Performance Materials to launch rare earths production program in US and Europe click here - Tartisan Nickel Corp (CSE:TN) (OTCMKTS:TTSRF) (FRA:8TA) poised for geophysical survey at flagship Kenbridge nickel-copper-cobalt project click here - Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) says it received 'positive' results from its Maximum Tolerated Dosage study of AME-1 click here - Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) (FRA:P731) doubles fiscal 3Q revenue to record C$31.5M click here - Q BioMed Inc (OTCQB:QBI
Gainers Reshape Lifesciences (NASDAQ:RSLS) stock rose 30.2% to $0.27 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.8 million shares, which is 104.8 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million. Cognition Therapeutics (NASDAQ:CGTX) shares rose 11.57% to $1.35. The market value of their outstanding shares is at $40.9 million. GRI Bio (NASDAQ:GRI) shares increased by 10.08% to $1.2. The company's market cap stands at $3.5 million. Vicarious Surgical (NYSE:RBOT) shares moved upwards by 10.06% to $0.41. The company's market cap stands at $70.6 million. AcelRx Pharm
Gainers INVO Bioscience, Inc. (NASDAQ:INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. LumiraDx Limited (NASDAQ:LMDX) shares climbed 187.4% to $0.25 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub. Akumin Inc. (NASDAQ:AKU) shares climbed 125% to $0.3279 after the company reached an agreement with Stonepeak to become a private company. Textainer Group Holdings Limited (NYSE:TGH) shares gained 44.5% to $49.33 after the company agreed to be acquired by Stonepeak for $7.4 billion. Twin Ridge Capital Acquisition Co
Gainers LumiraDx (NASDAQ:LMDX) shares increased by 281.2% to $0.34 during Monday's pre-market session. The company's market cap stands at $108.5 million. INVO Bioscience (NASDAQ:INVO) stock rose 185.18% to $1.54. The market value of their outstanding shares is at $3.7 million. Apollomics (NASDAQ:APLM) stock moved upwards by 33.71% to $2.34. The company's market cap stands at $209.3 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock increased by 14.8% to $0.42. The company's market cap stands at $3.4 million. AcelRx Pharmaceuticals (NASDAQ:ACRX) stock moved upwards by 12.39% to $0.63. The company's market cap stands at $10.2 million. SomaLogic (NASDAQ:SLGC) stock rose 12.0% to $2.52. T
Gainers Lipella Pharmaceuticals (NASDAQ:LIPO) stock increased by 43.5% to $2.31 during Friday's pre-market session. The company's market cap stands at $13.4 million. Aravive (NASDAQ:ARAV) stock increased by 17.18% to $0.17. The company's market cap stands at $12.1 million. American Well (NYSE:AMWL) stock rose 16.56% to $1.1. The company's market cap stands at $313.1 million. Akso Health Group (NASDAQ:AHG) stock rose 11.99% to $1.4. The company's market cap stands at $32.0 million. Comera Life Sciences (NASDAQ:CMRA) stock increased by 11.46% to $0.3. The market value of their outstanding shares is at $9.1 million. 180 Life Sciences (NASDAQ:ATNF) shares increased by 11.24% to $0.5. The m
Gainers SeaStar Medical Holding Corporation (NASDAQ:ICU) shares climbed 36.4% to $1.0516. SeaStar medical shares jumped 70% on Wednesday after the FDA granted the company's Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome. Outlook Therapeutics, Inc. (NASDAQ:OTLK) jumped 33.6% to $0.6304. MMTec, Inc. (NASDAQ:MTC) rose 32% to $1.7929. Atreca, Inc. (NASDAQ:BCEL) shares gained 28.8% to $0.3490. On Sept. 21, Atreca announced the termination of the lease at its corporate headquarters and the departure of the company's CFO. Spectral AI, Inc. (NASDAQ:MDAI) gained 26.7% to $3.2803. Spectral AI said that its DeepView SnapShot® Wound Imaging System is now
Gainers Ontrak (NASDAQ:OTRKP) shares moved upwards by 41.4% to $0.49 during Thursday's regular session. SeaStar Medical Holding (NASDAQ:ICU) stock rose 38.63% to $1.07. As of 13:30 EST, SeaStar Medical Holding's stock is trading at a volume of 113.1 million, which is 1149.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.7 million. Outlook Therapeutics (NASDAQ:OTLK) stock moved upwards by 35.58% to $0.64. As of 13:30 EST, Outlook Therapeutics's stock is trading at a volume of 106.5 million, which is 1616.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $166.4 million.
Gainers Nxu, Inc. (NASDAQ:NXU) shares surged 56.4% to $0.1079 in pre-market trading. On Oct. 17, Nxu received formal notice from Nasdaq staff that hearing is scheduled to be held on Dec. 14, 2023. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) shares rose 45.1% to $0.7981 in pre-market trading after gaining around 7% on Wednesday. SeaStar Medical Holding Corporation (NASDAQ:ICU) shares gained 34.9% to $1.04 in pre-market trading. SeaStar medical shares jumped 70% on Wednesday after the FDA granted the company's Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome. Atreca, Inc. (NASDAQ:BCEL) shares climbed 26.9% to $0.3440 in pre-market trading. On
Gainers Shift Technologies, Inc. (NASDAQ:SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Treasure Global Inc. (NASDAQ:TGL) climbed 65.1% to $0.5150 after the company announced an AI robot designed to conduct extended-hour live commerce sessions on TikTok. SeaStar Medical Holding Corporation (NASDAQ:ICU) shares climbed 45.3% to $0.6589 after the FDA granted the company’s Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome. RVL Pharmaceuticals plc (NASDAQ:RVLP) shares gained 31.4% to $0.0670 after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12, the company receive
Gainers SeaStar Medical Holding (NASDAQ:ICU) shares rose 52.9% to $0.69 during Wednesday's regular session. Trading volume for SeaStar Medical Holding's stock is 114.9 million as of 13:30 EST. This is 1614.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.4 million. Streamline Health Solns (NASDAQ:STRM) stock moved upwards by 26.23% to $0.38. As of 13:30 EST, Streamline Health Solns's stock is trading at a volume of 1.2 million, which is 519.9% of its average full-day volume over the last 100 days. The company's market cap stands at $22.3 million. Biocept (NASDAQ:BIOC) shares rose 20.54% to $0.62. Trading volume for Biocept's
Gainers Biocept (NASDAQ:BIOC) stock moved upwards by 48.9% to $0.76 during Wednesday's pre-market session. The company's market cap stands at $1.9 million. RVL Pharmaceuticals (NASDAQ:RVLP) stock moved upwards by 47.05% to $0.07. The market value of their outstanding shares is at $8.3 million. Baudax Bio (NASDAQ:BXRX) shares moved upwards by 42.49% to $0.28. The market value of their outstanding shares is at $2.6 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 19.05% to $0.54. The market value of their outstanding shares is at $10.4 million. Synaptogenix (NASDAQ:SNPX) stock moved upwards by 16.31% to $0.37. The market value of their outstanding shares is at $3.7 million. Yiel